Secukinumab, sold under the brand name Cosentyx, is a biologic medication used to treat several autoimmune conditions. While there are no generic versions of secukinumab currently available in the United States, the landscape for its patent exclusivity and potential biosimilar entry is evolving.
When does secukinumab patent exclusivity end?
The patent protection for secukinumab is complex, involving multiple patents covering its composition, method of use, and manufacturing processes. Information regarding the exact expiry dates of these patents and any related exclusivity periods can be found on DrugPatentWatch.com [1]. These dates are crucial for determining when biosimilar versions might become available.
What are biosimilars and how do they relate to secukinumab?
Biosimilars are biological products that are highly similar to an approved biological product, known as the reference product, with no clinically meaningful differences in terms of safety, purity, and potency. For secukinumab, a biosimilar would be a similar product that could potentially offer a lower-cost alternative once patent exclusivity has expired and regulatory approval is obtained.
How are companies challenging secukinumab patents?
Companies looking to bring biosimilar versions of secukinumab to market often challenge the existing patents held by the originator. These challenges can involve legal proceedings that aim to invalidate or narrow the scope of these patents, potentially paving the way for earlier biosimilar entry.
What are the key conditions secukinumab treats?
Secukinumab is approved for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and active psoriatic arthritis in pediatric patients [2]. It works by targeting interleukin-17A, a cytokine involved in the inflammatory processes of these diseases.
What clinical data supports secukinumab's effectiveness?
Numerous clinical trials have demonstrated the efficacy of secukinumab in managing symptoms and improving patient outcomes across its approved indications. These studies typically assess endpoints such as skin clearance in psoriasis, joint symptom reduction in psoriatic arthritis and ankylosing spondylitis, and radiographic progression [2].
What are the potential risks and side effects of secukinumab?
Like all medications, secukinumab carries potential risks and side effects. Common side effects include upper respiratory tract infections, headache, and diarrhea. More serious risks, though less common, can involve serious infections, including tuberculosis, and a potential increased risk of certain cancers [2]. Patients should discuss these with their healthcare provider.
Who are the main competitors to secukinumab?
In the treatment of inflammatory diseases, secukinumab competes with other biologic therapies that target different pathways involved in the inflammatory cascade. These include other IL-17 inhibitors, as well as drugs targeting TNF-alpha, IL-12/23, and IL-23 [3].
What is the typical cost of secukinumab treatment?
The cost of secukinumab can be substantial, reflecting the nature of biologic therapies. Pricing information and potential assistance programs are subjects of interest for patients and healthcare providers. Factors influencing the cost include dosage, treatment duration, and insurance coverage.
Can biosimilars enter the market before patent expiry?
Generally, biosimilars cannot enter the market before the expiry of relevant patents and any associated exclusivity periods. However, patent litigation can sometimes lead to settlements or court decisions that alter these timelines.
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.cosentyx.com/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6901432/